• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by NANO-X IMAGING LTD (Amendment)

    3/7/24 12:29:51 PM ET
    $NNOX
    Medical Electronics
    Health Care
    Get the next $NNOX alert in real time by email
    SC 13G/A 1 il0011681371_030624.txt il0011681371_030624.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 1) NANO-X IMAGING LTD -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) BLB2P06 -------------------------------------------------------- (SEDOL Number) February 29, 2024 -------------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). SEDOL No. BLB2P06 (1)Names of reporting persons. BlackRock, Inc. (2) Check the appropriate box if a member of a group (a) [ ] (b) [X] (3) SEC use only (4) Citizenship or place of organization Delaware Number of shares beneficially owned by each reporting person with: (5) Sole voting power 2584831 (6) Shared voting power 0 (7) Sole dispositive power 2644621 (8) Shared dispositive power 0 (9) Aggregate amount beneficially owned by each reporting person 2644621 (10) Check if the aggregate amount in Row (9) excludes certain shares (11) Percent of class represented by amount in Row 9 4.6% (12) Type of reporting person HC Item 1. Item 1(a) Name of issuer: ----------------------------------------------------------------------- NANO-X IMAGING LTD Item 1(b) Address of issuer's principal executive offices: ----------------------------------------------------------------------- OFER TECH PARK, 94 SHLOMO SHMELTZER ROAD PETACH TIKVA Israel 4970602 Item 2. 2(a) Name of person filing: ---------------------------------------------------------------------- BlackRock, Inc. 2(b) Address or principal business office or, if none, residence: ----------------------------------------------------------------------- BlackRock, Inc. 50 Hudson Yards New York, NY 10001 2(c) Citizenship: -------------------------------------------------------------------- See Item 4 of Cover Page 2(d) Title of class of securities: ------------------------------------------------------------------- Common Stock 2(e) SEDOL No.: See Cover Page Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a: [ ] Broker or dealer registered under Section 15 of the Act; [ ] Bank as defined in Section 3(a)(6) of the Act; [ ] Insurance company as defined in Section 3(a)(19) of the Act; [ ] Investment company registered under Section 8 of the Investment Company Act of 1940; [ ] An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E); [ ] An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F); [X] A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G); [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940; [ ] A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J); [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: Item 4. Ownership Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. Amount beneficially owned: 2644621 Percent of class 4.6% Number of shares as to which such person has: Sole power to vote or to direct the vote 2584831 Shared power to vote or to direct the vote 0 Sole power to dispose or to direct the disposition of 2644621 Shared power to dispose or to direct the disposition of 0 Item 5. Ownership of 5 Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [ X ]. Item 6. Ownership of More than 5 Percent on Behalf of Another Person [ N/A ] Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. See Exhibit A Item 8. Identification and Classification of Members of the Group If a group has filed this schedule pursuant to Rule 13d-1(b)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identity of each member of the group. Item 9. Notice of Dissolution of Group Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5. Item 10. Certifications By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: March 6, 2024 BlackRock, Inc. Signature: Spencer Fleming ------------------------------------------- Name/Title Attorney-In-Fact The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature. Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001). Exhibit A Subsidiary BlackRock Advisors, LLC BlackRock Asset Management Canada Limited BlackRock Fund Advisors BlackRock Asset Management Ireland Limited BlackRock Institutional Trust Company, National Association BlackRock Financial Management, Inc. BlackRock Fund Managers Ltd BlackRock Asset Management Schweiz AG BlackRock Investment Management, LLC *Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G. Exhibit B POWER OF ATTORNEY The undersigned, BlackRock, Inc., a corporation duly organized under the laws of the State of Delaware, United States (the "Company"), does hereby make, constitute and appoint each of Eric Andruczyk, Richard Cundiff, R. Andrew Dickson, III, Spencer Fleming, Daniel Goldmintz, Laura Hildner, Elizabeth Kogut, David Maryles, Christopher Meade, Una Neary, Charles Park, Daniel Riemer, David Rothenberg and Brenda Schulz, acting severally, as its true and lawful attorneys-in-fact, for the purpose of, from time to time, executing, in its name and on its behalf and on behalf of its direct and indirect subsidiaries, any and all documents, certificates, instruments, statements, filings, agreements and amendments (collectively, "documents") determined by such person to be necessary or appropriate to comply with ownership or control-person reporting requirements imposed by any United States or non-United States governmental or regulatory authority, including, without limitation, Schedules 13D and 13G and Forms 3, 4, 5, 13F and 13H and any amendments to any of the foregoing as may be required to be filed with the Securities and Exchange Commission, and delivering, furnishing or filing any such documents with the appropriate governmental or regulatory authority or other person, and giving and granting to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully and to all intents and purposes as the Company and/or its direct and indirect subsidiaries, as applicable, might or could do if personally present by one of its authorized signatories, hereby ratifying and confirming all that said attorney-in-fact shall lawfully do or cause to be done by virtue hereof. Any such determination by an attorney-in-fact named herein shall be conclusively evidenced by such person's execution, delivery, furnishing or filing of the applicable document. This power of attorney shall expressly revoke the power of attorney dated 2nd day of January, 2019 in respect of the subject matter hereof, shall be valid from the date hereof and shall remain in full force and effect until either revoked in writing by the Company, or, in respect of any attorney-in-fact named herein, until such person ceases to be an employee of the Company or one of its affiliates. IN WITNESS WHEREOF, the undersigned has caused this power of attorney to be executed as of this 30th day of April, 2023. BlackRock, Inc. By: /s/ R. Andrew Dickson, III Name: R. Andrew Dickson, III Title: Corporate Secretary
    Get the next $NNOX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NNOX

    DatePrice TargetRatingAnalyst
    1/6/2025$23.00Buy
    D. Boral Capital
    9/8/2023$14.50Buy
    Alliance Global Partners
    1/5/2023$21.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $NNOX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Nanox to Report First Quarter 2025 Financial Results on May 22, 2025

      PETACH TIKVA, Israel, May 08, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ((", Nanox", or the ", Company", , NASDAQ:NNOX), an innovative medical imaging technology company, today announced that it will report its financial results for the quarter ended March 31, 2025, before market open on Thursday, May 22, 2025. Erez Meltzer, Chief Executive Officer and Acting Chairman, and Ran Daniel, Chief Financial Officer, will host a conference call to review these results and provide a business update beginning at 8:30 a.m. ET. Interested parties may register for the conference call using the following link: Nanox Q1 2025 Earnings Call Registration. The live webcast of the conference call may be

      5/8/25 4:03:00 PM ET
      $NNOX
      Medical Electronics
      Health Care
    • Nanox Receives FDA Clearance for General Use of New Imaging System, Nanox.ARC X

      First FDA clearance for Nanox.ARC X to produce tomographic images for general use, including musculoskeletal, pulmonary, intra-abdominal and paranasal indicationsEnhanced imaging system features sleek design with smaller footprint; simplified ‘plug and play' installation processSystem design enables software upgrades and new capabilities to be added remotely following future regulatory clearances PETACH TIKVA, Israel, April 17, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ((", Nanox", or the ", Company", , NASDAQ:NNOX), an innovative medical imaging technology company, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the Nanox.ARC X

      4/17/25 8:30:54 AM ET
      $NNOX
      Medical Electronics
      Health Care
    • Nanox to Present New Data Featuring AI Bone Solution at Four Medical Conferences through June 2025 across Europe

      ADOPT Study Findings Highlight Nanox.AI's Role in Enhancing Fracture Detection and Healthcare Cost Savings PETACH TIKVA, Israel, March 26, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ((", Nanox", or the ", Company", , NASDAQ:NNOX), an innovative medical imaging technology company, today announced that its deep-learning medical imaging analytics subsidiary, Nanox AI Ltd will present new data from the AI-enabled Detection of OsteoPorosis for Treatment (ADOPT) study at four major upcoming medical conferences spanning March through June 2025. The ADOPT study concluded in February 2025 and evaluated HealthVCF at four National Health Services (NHS) trusts: Cambridge, Bradford, Cardiff and

      3/26/25 7:00:13 AM ET
      $NNOX
      Medical Electronics
      Health Care

    $NNOX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • D. Boral Capital initiated coverage on Nano-X Imaging with a new price target

      D. Boral Capital initiated coverage of Nano-X Imaging with a rating of Buy and set a new price target of $23.00

      1/6/25 9:02:00 AM ET
      $NNOX
      Medical Electronics
      Health Care
    • Alliance Global Partners initiated coverage on Nano-X Imaging with a new price target

      Alliance Global Partners initiated coverage of Nano-X Imaging with a rating of Buy and set a new price target of $14.50

      9/8/23 9:14:06 AM ET
      $NNOX
      Medical Electronics
      Health Care
    • Cantor Fitzgerald initiated coverage on Nano-X Imaging with a new price target

      Cantor Fitzgerald initiated coverage of Nano-X Imaging with a rating of Overweight and set a new price target of $21.00

      1/5/23 7:46:34 AM ET
      $NNOX
      Medical Electronics
      Health Care

    $NNOX
    Leadership Updates

    Live Leadership Updates

    See more
    • Nanox Announces Appointment of Medical Executive Moshe Shtengel as Chief Business Officer

      NEVE ILAN, Israel, May 03, 2021 (GLOBE NEWSWIRE) -- NANOX IMAGING LTD (NASDAQ:NNOX) ("Nanox" or the "Company"), an innovative medical imaging technology company, announced today the appointment of Moshe Shtengel as Chief Business Officer, effective May 2, 2021. Mr. Shtengel joins Nanox from Tuttnauer, a global manufacturer of sterilizers and infection control systems for medical institutions, where he served as Vice President of Global Sales, Marketing and Products. "Moshe is an extremely seasoned sales and business development executive with a proven track record of success and leadership in the medical field," stated Ran Poliakine, Chairman and Chief Executive Officer of Nanox. "As we

      5/3/21 8:00:00 AM ET
      $NNOX
      Medical Electronics
      Health Care

    $NNOX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by NANO-X IMAGING LTD (Amendment)

      SC 13G/A - Nano-X Imaging Ltd. (0001795251) (Subject)

      3/7/24 12:29:51 PM ET
      $NNOX
      Medical Electronics
      Health Care
    • SEC Form SC 13G filed by NANO-X IMAGING LTD

      SC 13G - Nano-X Imaging Ltd. (0001795251) (Subject)

      2/6/24 9:36:34 AM ET
      $NNOX
      Medical Electronics
      Health Care
    • SEC Form SC 13G/A filed by NANO-X IMAGING LTD (Amendment)

      SC 13G/A - Nano-X Imaging Ltd. (0001795251) (Subject)

      2/14/23 4:15:16 PM ET
      $NNOX
      Medical Electronics
      Health Care

    $NNOX
    SEC Filings

    See more
    • SEC Form 6-K filed by NANO-X IMAGING LTD

      6-K - Nano-X Imaging Ltd. (0001795251) (Filer)

      4/17/25 8:40:02 AM ET
      $NNOX
      Medical Electronics
      Health Care
    • SEC Form 20-F filed by NANO-X IMAGING LTD

      20-F - Nano-X Imaging Ltd. (0001795251) (Filer)

      4/9/25 4:29:36 PM ET
      $NNOX
      Medical Electronics
      Health Care
    • SEC Form 6-K filed by NANO-X IMAGING LTD

      6-K - Nano-X Imaging Ltd. (0001795251) (Filer)

      3/31/25 8:37:25 AM ET
      $NNOX
      Medical Electronics
      Health Care

    $NNOX
    Financials

    Live finance-specific insights

    See more
    • Nanox to Report First Quarter 2025 Financial Results on May 22, 2025

      PETACH TIKVA, Israel, May 08, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ((", Nanox", or the ", Company", , NASDAQ:NNOX), an innovative medical imaging technology company, today announced that it will report its financial results for the quarter ended March 31, 2025, before market open on Thursday, May 22, 2025. Erez Meltzer, Chief Executive Officer and Acting Chairman, and Ran Daniel, Chief Financial Officer, will host a conference call to review these results and provide a business update beginning at 8:30 a.m. ET. Interested parties may register for the conference call using the following link: Nanox Q1 2025 Earnings Call Registration. The live webcast of the conference call may be

      5/8/25 4:03:00 PM ET
      $NNOX
      Medical Electronics
      Health Care
    • Nanox to Report Fourth Quarter and Fiscal Year 2024 Financial Results on March 31, 2025

      PETACH TIKVA, Israel, March 17, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ((", Nanox", or the ", Company", , NASDAQ:NNOX), an innovative medical imaging technology company, today announced that it will report its financial results for the quarter and fiscal year ended December 31, 2024, before market open on Monday, March 31, 2025. Erez Meltzer, Chief Executive Officer and Acting Chairman, and Ran Daniel, Chief Financial Officer, will host a conference call to review these results and provide a business update beginning at 8:30 a.m. ET. Interested parties may register for the conference call using the following link: Nanox Q4 Earnings Call Registration. The live webcast of the conferenc

      3/17/25 4:05:00 PM ET
      $NNOX
      Medical Electronics
      Health Care
    • Nanox Announces Third Quarter of 2024 Financial Results and Provides Business Update

      Made progress deploying all components of the Nanox solution including Nanox.ARC and Nanox.AI Expanded US sales and support staff a key component of global strategic growth plan Management to host conference call and webcast Thursday, November 21, 2024 at 8:30 AM ET PETACH TIKVA, Israel, Nov. 21, 2024 (GLOBE NEWSWIRE) -- November 21, 2024 — NANO-X IMAGING LTD (NASDAQ:NNOX) ("Nanox" or the "Company"), an innovative medical imaging technology company, today announced results for the third quarter ended September 30, 2024 and provided a business update. Recent Highlights: Generated $3.0 million in revenue in the third quarter of 2024, compared to $2.5 million in the third quarter of 2023

      11/21/24 8:00:00 AM ET
      $NNOX
      Medical Electronics
      Health Care